1 / 22

Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon

Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon. Daniel Bessesen , MD. Low. High. Currently Available Options. Effectiveness. Accept weight where it is Diet/Exercise: 3-10% weight loss Drugs: 5-12% weight loss Medically Supervised/Combination

donar
Download Presentation

Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon Daniel Bessesen, MD

  2. Low High Currently Available Options Effectiveness • Accept weight where it is • Diet/Exercise: 3-10% weight loss • Drugs: 5-12% weight loss • Medically Supervised/Combination of Diet + Drug: 10-15% weight loss • Surgery: 15-30% weight loss

  3. Low High Currently Available Options Risks/Time/Money • Accept weight where it is • Diet/Exercise: 3-10% weight loss • Drugs: 5-12% weight loss • Medically Supervised/Combination of Diet + Drug: 10-15% weight loss • Surgery: 15-30% weight loss

  4. A Guide to Selecting Treatment Body Mass Index category Treatment 25-26.9 27-29.9 30-34.9 35-39.9 40 Diet, physical activity, and behavior therapy With co-morbidity + + + + With co-morbidity + + + Pharmacotherapy With co-morbidity + Surgery NIH The Practical Guide. 2000 http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.htm 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437739.71477.ee.citation

  5. Surgery Pharmacotherapy Lifestyle Modification Diet Physical Activity Obesity Treatment Pyramid

  6. PharmacologicalTreatment of Obesity • Current medications 5-12% wt loss • Benefits only last as long as patient takes the medication. Chronic treatment likely needed. • Drugs probably not paid for by insurance so cost is a big issue for patients. • Issues of FDA approval, long term safety, and efficacy. • Are medications an appropriate treatment modality for obesity?

  7. New and Emerging Medications • FDA approved • Lorcasarin (Belviq) • Phentermine/topiramate ER (Qsymia) • May be approved in near future • Liraglutide • Bupropion/naltrexone

  8. Lorcasarin (Belviq) • Serotonin 2C receptor agonist • Previous serotonin agonists fenfluramine and dexfenfluramine caused cardiac valve disease, removed from market • 2C receptor only in the brain not in heart • Studies in 1-2,000 people for up to 2 years do not show evidence if valvulopathy with lorcasarin.

  9. Lorcasarin (Belviq) • Weight loss: 3-5% no better than phentermine or orlistat • Side effects: headache, dizziness and nausea • Cost: $220/month • Unclear if physicians will prescribe off label with phentermine (no data on safety or efficacy)

  10. Lorcasarin: Weight Effects N Engl J Med. 2010 Jul 15;363(3):245-56

  11. Phentermine/Topiramate • Combination gives greater effectiveness with fewer side effects • Cost: $150.00/month • Side effects: dry mouth, numbness, tingling, insomnia, dizziness, anxiety, irritability and disturbance in attention

  12. Topiramate/Phentermine (Qsymia) Effects on Weight Lancet. 2011 Apr 16;377(9774):1341-52

  13. Phentermine/Topiramate • Risk of birth defects: women need – pregnancy test on starting and monthly while using. • Reduces blood pressure, glucose, insulin, triglycerides and raises HDL • Unclear if physicians will prescribe off label using generic phentermine and topiramate. • Most effective medication available 10-12% weight loss.

  14. Lap Band Gastric Bypass Effectiveness High Low Risk

  15. Comparison of Operations • Lap band: 20% weight loss, very low mortality, 1% serious or 2.4% any complication • Sleeve gastrectomy: 25% weight loss, 0.1% mortality, 2.4% serious or 6.3% any complication • Gastric bypass: 30% weight loss, 0.2% mortality, 2.5% serious or 10% any complication Ann Surg 2013;257: 791–797; Flum DR, N Engl J Med. 2009 Jul 30;361(5):445-54

  16. Benefits of Weight Loss Surgery the Swedish Obese Subjects TrialBariatric Surgery vs. Usual Care • Nonrandomized prospective controlled study • 2010 pts. had surgery compared to 2037 contemporaneously matched controls • Began 1987 • Median follow up 14.7 years

  17. Weight loss in the SOS JAMA. 2012;307(1):56-65

  18. Bariatric Surgery is Associated with a Reduced Mortality: the SOS Study 30% lower risk Of dying MI: 25 in control Group 13 in the Surgery group Cancer: 47 in The control group 29 in the surgery group Sjostrom L NEJM 2007: 357-741-752

  19. Benefits of Bariatric Surgery for T2DMN Engl J Med 2012;366:1567-76 • 150 patients randomized to intensive medical therapy, gastric bypass or sleeve gastrectomy for management of type 2 diabetes • Average baseline A1C was 9.2% (diabetes >6.5, goal <7%) • Followed for 12 months

  20. Stampede Trial: Benefits of Surgery for Type 2 Diabetes N Engl J Med 2012;366:1567-76

  21. Who is a Good Candidate? • BMI>35 with co-morbidities or >40 without • Age 20-60 • Co-morbidities: Diabetes, sleep apnea, reflux > Hypertension, DJD • Failed other forms of therapy • No serious, active cardiac, pulmonary, or psychiatric disease

  22. Thank you

More Related